Rebecka L Meyers1, Greg Tiao, Jean de Ville de Goyet, Riccardo Superina, Daniel C Aronson. 1. aPediatric Surgery, Primary Children's Medical Center, University of Utah, Salt Lake City, Utah bPediatric Surgery, Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, USA cDepartment of Pediatric Surgery and Transplantation, Ospedale Pediatrico Bambino Gesù, University of Rome 'Tor Vergata', Italy dPediatric Surgery, Lurie Children's Hospital of Chicago, Chicago, Illinois, USA eQueen Elisabeth Central Hospital, College of Medicine, University of Malawi, Blantyre, Malawi.
Abstract
PURPOSE OF REVIEW: This is part two of a two-part state of the art--hepatoblastoma. International hepatoblastoma specialists were brought together to highlight advances, controversies, and future challenges in the treatment of this rare pediatric tumor. RECENT FINDINGS: Pretreatment extent of disease (PRETEXT) is a grouping system introduced as part of the multicenter international childhood liver tumors strategy group, SIOPEL-1, study in 1990. The system has been refined over the ensuing years and has now come to be adopted for risk stratification by all of the major pediatric liver tumor multicenter trial groups. PRETEXT is being intensively studied in the current Children's Oncology Group (COG) AHEP-0731 trial in an attempt to validate interobserver reproducibility and ability to monitor response to neoadjuvant chemotherapy, and determine surgical resectability. PRETEXT is now used to identify those patients who are at risk for having an unresectable tumor and who should be referred to a liver specialty center with transplant capability early in their treatment schema. SUMMARY: International collaborative efforts in hepatoblastoma have led to increased refinements in the use of the PRETEXT and post-treatment extent to define prognosis and surgical resectability. PRETEXT criteria which suggest a possible need for liver transplantation are discussed in detail.
PURPOSE OF REVIEW: This is part two of a two-part state of the art--hepatoblastoma. International hepatoblastoma specialists were brought together to highlight advances, controversies, and future challenges in the treatment of this rare pediatric tumor. RECENT FINDINGS: Pretreatment extent of disease (PRETEXT) is a grouping system introduced as part of the multicenter international childhood liver tumors strategy group, SIOPEL-1, study in 1990. The system has been refined over the ensuing years and has now come to be adopted for risk stratification by all of the major pediatric liver tumor multicenter trial groups. PRETEXT is being intensively studied in the current Children's Oncology Group (COG) AHEP-0731 trial in an attempt to validate interobserver reproducibility and ability to monitor response to neoadjuvant chemotherapy, and determine surgical resectability. PRETEXT is now used to identify those patients who are at risk for having an unresectable tumor and who should be referred to a liver specialty center with transplant capability early in their treatment schema. SUMMARY: International collaborative efforts in hepatoblastoma have led to increased refinements in the use of the PRETEXT and post-treatment extent to define prognosis and surgical resectability. PRETEXT criteria which suggest a possible need for liver transplantation are discussed in detail.
Authors: Howard M Katzenstein; Max R Langham; Marcio H Malogolowkin; Mark D Krailo; Alexander J Towbin; Mary Beth McCarville; Milton J Finegold; Sarangarajan Ranganathan; Stephen Dunn; Eugene D McGahren; Gregory M Tiao; Allison F O'Neill; Muna Qayed; Wayne L Furman; Caihong Xia; Carlos Rodriguez-Galindo; Rebecka L Meyers Journal: Lancet Oncol Date: 2019-04-08 Impact factor: 41.316
Authors: Alexander J Towbin; Rebecka L Meyers; Helen Woodley; Osamu Miyazaki; Christopher B Weldon; Bruce Morland; Eiso Hiyama; Piotr Czauderna; Derek J Roebuck; Greg M Tiao Journal: Pediatr Radiol Date: 2018-02-09
Authors: Christopher B Weldon; Arin L Madenci; Gregory M Tiao; Stephen P Dunn; Max R Langham; Eugene D McGahren; Sarangarajan Ranganathan; Dolores H López-Terrada; Milton J Finegold; Marcio H Malogolowkin; Jin Piao; Li Huang; Mark D Krailo; Rebecka L Meyers; Howard M Katzenstein Journal: J Pediatr Surg Date: 2019-05-11 Impact factor: 2.545
Authors: Allison F O'Neill; Alexander J Towbin; Mark D Krailo; Caihong Xia; Yun Gao; M Beth McCarville; Rebecka L Meyers; Eugene D McGahren; Greg M Tiao; Stephen P Dunn; Max R Langham; Christopher B Weldon; Milton J Finegold; Sarangarajan Ranganathan; Wayne L Furman; Marcio Malogolowkin; Carlos Rodriguez-Galindo; Howard M Katzenstein Journal: J Clin Oncol Date: 2017-09-11 Impact factor: 44.544